Bioventus Inc. (BVS) stock

BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Nov 2, 2026Score 14/3033% below fair value

$10.86−0.13 (-1.18%)

Close on Nov 12, 2026Market cap $913.24MP/E 13.6Yield –

Bioventus operating margin

Operating margin is operating income as a percentage of revenue.

Bioventus's operating margin for the twelve months ending Sep 26, 2026 was 9.7%. For fiscal 2025 it was 9.5%, against -2.7% the year before. The highest annual figure on record is 9.5% in fiscal 2025.

Annual operating margin

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	9.5%	+12.2
FY2024	Dec 31, 2024	-2.7%	+13.3
FY2023	Dec 31, 2023	-16.0%	+16.7
FY2022	Dec 31, 2022	-32.7%	−35.5
FY2021	Dec 31, 2021	2.8%	−3.8
FY2020	Dec 31, 2020	6.6%	−2.6
FY2019	Dec 31, 2019	9.2%	–

Quarterly operating margin

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q3 FY2026	Sep 26, 2026	6.8%	−1.3
Q2 FY2026	Jun 27, 2026	12.5%	+0.0
Q1 FY2026	Mar 28, 2026	6.4%	+2.4
Q4 FY2025	Dec 31, 2025	12.3%	+7.3
Q3 FY2025	Sep 27, 2025	8.1%	+5.5
Q2 FY2025	Jun 28, 2025	12.4%	+33.3
Q1 FY2025	Mar 29, 2025	3.9%	+0.1
Q4 FY2024	Dec 31, 2024	5.0%	+4.2
Q3 FY2024	Sep 28, 2024	2.6%	+0.6
Q2 FY2024	Jun 29, 2024	-20.8%	−25.7
Q1 FY2024	Mar 30, 2024	3.8%	+81.1
Q4 FY2023	Dec 31, 2023	0.9%	+13.3
Q3 FY2023	Sep 30, 2023	2.0%	+100.6
Q2 FY2023	Jul 1, 2023	4.9%	+7.3
Q1 FY2023	Apr 1, 2023	-77.3%	−59.0
Q4 FY2022	Dec 31, 2022	-12.4%	−10.0
Q3 FY2022	Oct 1, 2022	-98.6%	−97.6
Q2 FY2022	Jul 2, 2022	-2.4%	+2.9
Q1 FY2022	Apr 2, 2022	-18.3%	−45.2
Q4 FY2021	Dec 31, 2021	-2.4%	−8.4
Q3 FY2021	Oct 2, 2021	-1.0%	−9.0
Q2 FY2021	Jul 3, 2021	-5.2%	+2.7
Q1 FY2021	Apr 3, 2021	26.9%	+10.4
Q4 FY2020	Dec 31, 2020	6.0%	–
Q3 FY2020	Sep 26, 2020	8.1%	–
Q2 FY2020	Jun 27, 2020	-7.9%	–
Q1 FY2020	Mar 28, 2020	16.5%	–